HWK-016 for Ovarian Cancer

This trial tests a new treatment called HWK-016, targeting ovarian and endometrial cancers. The goal is to determine if HWK-016, alone or with another drug called bevacizumab, is safe and effective for individuals with advanced cancer. Researchers adjust the dose during different trial phases to find the optimal one. Those with advanced ovarian or endometrial cancer might find this trial suitable. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this new treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

In a previous study, HWK-016, a special type of treatment, proved very effective in treating solid tumors. Since HWK-016 is being tested in humans for the first time, detailed safety information from people is not yet available. The study is currently in Phase 1, focusing on assessing the treatment's safety and tolerability.

Phase 1 studies generally aim to find the safest dose and identify any side effects. The progression to Phase 1 indicates that HWK-016 showed some safety promise in earlier lab tests before human trials.

Researchers are excited about HWK-016 for ovarian cancer because it targets the MUCIN-16 protein, which is overexpressed in many ovarian tumors. Unlike standard treatments like chemotherapy, which can affect both cancerous and healthy cells, HWK-016 is an antibody-drug conjugate (ADC) that delivers a cytotoxic agent directly to the cancer cells, potentially reducing side effects. Additionally, some trial arms are exploring HWK-016 in combination with Bevacizumab, a drug that inhibits tumor blood vessel growth, potentially enhancing the overall treatment effectiveness. This targeted approach offers a new hope for more efficient and less harmful ovarian cancer treatment.

Research has shown that HWK-016 targets a protein called MUCIN-16, which appears in large amounts in ovarian cancer cells. Studies indicate that MUCIN-16 is much more prevalent in ovarian cancer than in other conditions, making it a promising treatment target. Early lab tests demonstrated that HWK-016 can specifically attach to cancer cells and shrink tumors, even at low doses. In this trial, some participants will receive HWK-016 alone, while others will receive it in combination with Bevacizumab, a drug known to enhance treatment effects in ovarian cancer. This combination holds promise for even better results. While these findings are encouraging, further research is needed to confirm HWK-016's effectiveness in people.¹²³⁶⁷